The therapeutic synergy between fungal β-glucans and CD40 agonism demonstrates that components of the mycobiota, or their molecular analogs, can be leveraged to overcome tumor-induced immunosuppression, particularly in settings where conventional checkpoint inhibition fails. Here, CD40 is linked to neoplasm.